-
EP3860430
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3860430
| EP3860430 - DIGITAL BIOMARKERS FOR ASSESSING SCHIZOPHRENIA [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 02.06.2023 Database last updated on 12.07.2024 | |
| Former | Request for examination was made Status updated on 09.07.2021 | ||
| Former | The international publication has been made Status updated on 11.04.2020 | ||
| Former | unknown Status updated on 08.10.2019 | Most recent event Tooltip | 06.12.2023 | New entry: Reply to examination report | Applicant(s) | For all designated states F. Hoffmann-La Roche AG Grenzacherstrasse 124 4070 Basel / CH | [2021/32] | Inventor(s) | 01 /
GOSSENS, Christian c/o F. Hoffmann-La Roche AG Grenzacherstrasse 124 4070 Basel / CH | 02 /
KILCHENMANN, Timothy c/o F. Hoffmann-La Roche AG Grenzacherstrasse 124 4070 Basel / CH | 03 /
LINDEMANN, Michael c/o Inovigate GmbH Aeschenvorstadt 55 4051 Basel / CH | [2021/32] | Representative(s) | Altmann Stößel Dick Patentanwälte PartG mbB Theodor-Heuss-Anlage 2 68165 Mannheim / DE | [N/P] |
| Former [2021/32] | Altmann Stößel Dick Patentanwälte PartG mbB Dudenstrasse 46 68167 Mannheim / DE | Application number, filing date | 19779051.2 | 04.10.2019 | [2021/32] | WO2019EP76972 | Priority number, date | EP20180198954 | 05.10.2018 Original published format: EP 18198954 | [2021/32] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2020070318 | Date: | 09.04.2020 | Language: | EN | [2020/15] | Type: | A1 Application with search report | No.: | EP3860430 | Date: | 11.08.2021 | Language: | EN | The application published by WIPO in one of the EPO official languages on 09.04.2020 takes the place of the publication of the European patent application. | [2021/32] | Search report(s) | International search report - published on: | EP | 09.04.2020 | Classification | IPC: | A61B5/00, G16H40/63, G16H50/20 | [2021/32] | CPC: |
G16H50/20 (EP,US);
A61B5/165 (US);
A61B5/0022 (EP,US);
A61B5/1118 (EP,US);
A61B5/168 (EP,US);
A61B5/4833 (EP);
A61B5/4842 (EP,US);
A61B5/6898 (EP,US);
G16H20/70 (US);
G16H40/63 (EP);
G16H40/67 (US);
A61B2560/0242 (EP,US);
A61B2562/0204 (EP);
A61B2562/0219 (EP,US);
A61B2562/0223 (US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/32] | Title | German: | DIGITALE BIOMARKER ZUR BEURTEILUNG VON SCHIZOPHRENIE | [2021/32] | English: | DIGITAL BIOMARKERS FOR ASSESSING SCHIZOPHRENIA | [2021/32] | French: | BIOMARQUEURS NUMÉRIQUES POUR ÉVALUER LA SCHIZOPHRÉNIE | [2021/32] | Entry into regional phase | 31.03.2021 | National basic fee paid | 31.03.2021 | Designation fee(s) paid | 31.03.2021 | Examination fee paid | Examination procedure | 31.03.2021 | Examination requested [2021/32] | 31.03.2021 | Date on which the examining division has become responsible | 23.11.2021 | Amendment by applicant (claims and/or description) | 02.06.2023 | Despatch of a communication from the examining division (Time limit: M06) | 06.12.2023 | Reply to a communication from the examining division | Fees paid | Renewal fee | 23.10.2021 | Renewal fee patent year 03 | 21.10.2022 | Renewal fee patent year 04 | 19.10.2023 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]US9521973 (BEISKI BEN [IL], et al) [A] 1-15 * the whole document, in particular claims 1, 4-7 *; | [A]WO2018102867 (COGNIANT PTY LTD [AU]) [A] 1-15 * the whole document, in particular claims 9, 10, 12-15 *; | [XI] - T F D FARROW ET AL, "Modafinil and unconstrained motor activity in schizophrenia: double-blind crossover placebo-controlled trial", THE BRITISH JOURNAL OF PSYCHIATRY, (20061101), vol. 189, pages 461 - 462, XP055553616 [X] 1-4,11,12 * the whole document, in particular summary; page 461, middle column, lines 31-36; page 461, right column, line 30 to page 462, left column, line 7; figure 1 * [I] 5-10,13-15 | [XI] - J ZHANG ET AL, "Clinical investigation of speech signal features among patients with schizophrenia", SHANGHAI ARCHIVES OF PSYCHIATRY, (20160425), vol. 28, no. 2, pages 95 - 102, XP055553574 [X] 1,2,5,7,11,12 * the whole document, in particular abstract; section 2.2 on page 97; figure 1; tables 1, 3; page 100, left column, paragraph 3 * [I] 3,6,13-15 | [XAI] - R T Wang, "MENTAL HEALTH SENSING USING MOBILE PHONES", Thesis, Dartmouth College, Hanover, New Hampshire, USA, (20180928), URL: https://www.cs.dartmouth.edu/~campbell/dr_rui_wang_thesis-2018.pdf, (20190207), XP055553365 [X] 1,5,7,11-15 * the whole document, in particular sections 1.1.1 on pages 3-6 and sections 4-6 on pages 102-192 * [A] 8-10 [I] 3,6 | [XAI] - S SHIN ET AL, "Activity monitoring using a mHealth device and correlations with psychopathology in patients with chronic schizophrenia", PSYCHIATRY RESEARCH, (20161031), vol. 246, doi:10.1016/J.PSYCHRES.2016.10.059, pages 712 - 718, XP029847036 [X] 1,2,4,5,7,11,12,14,15 * the whole document, in particular abstract; sections 2.2.1 and 2.2.2 on page 713; table 3 * [A] 8-10 [I] 3,6,13 DOI: http://dx.doi.org/10.1016/j.psychres.2016.10.059 | [X] - I BARNETT ET AL, "Relapse prediction in schizophrenia through digital phenotyping: a pilot study", NEUROPSYCHOPHARMACOLOGY, (20180222), vol. 43, no. 8, doi:10.1038/s41386-018-0030-z, pages 1660 - 1666, XP055552443 [X] 1,2,4,5,7,11-15 * the whole document, in particular abstract; table 2; page 1663, column 2, first paragraph of "disussion" * DOI: http://dx.doi.org/10.1038/s41386-018-0030-z | [ID] - J TOROUS ET AL, "New Tools for New Research in Psychiatry: A Scalable and Customizable Platform to Empower Data Driven Smartphone Research", JMIR MENTAL HEALTH, (20160505), vol. 3, no. 2, doi:10.2196/mental.5165, page e16, XP055553034 [ID] 1,7-10 * the whole document, in particular abstract; figure 1; page 4, section "characteristics of reasearch platform and research data"; page 5, section "global positioning system and accelerometer" to page 9, section "phone and screen status"; figure 10 * DOI: http://dx.doi.org/10.2196/mental.5165 | [A] - E REINERTSEN ET AL, "A review of physiological and behavioral monitoring with digital sensors for neuropsychiatric illnesses", PHYSIOLOGICAL MEASUREMENT, (20180515), vol. 39, doi:10.1088/1361-6579/aabf64, page 05TR01, XP055553338 [A] 1-15 * the whole document, in particular sections 2.3, 3.3, 5 * DOI: http://dx.doi.org/10.1088/1361-6579/aabf64 | [A] - S KUMARI ET AL, "An Assessment of Five (PANSS, SAPS, SANS, NSA-16, CGI-SCH) commonly used Symptoms Rating Scales in Schizophrenia and Comparison to Newer Scales (CAINS, BNSS)", JOURNAL OF ADDICTION RESEARCH & THERAPY, (20170511), vol. 08, no. 03, doi:10.4172/2155-6105.1000324, XP055553391 [A] 1-15 * the whole document * DOI: http://dx.doi.org/10.4172/2155-6105.1000324 | by applicant | - TOROUS, JMIR Mental Health, (20160000), vol. 3, no. 2, page e16 | - WANG, The 2016 ACM International Joint Conference on Pervasive and Ubiquitous Computing (UbiComp 2016, (20160000), ISBN 978-1-4503-4461-6, pages 886 - 897 |